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Abstract
Background: Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU), is unique among human pathogens in its
capacity to produce a polyketide-derived macrolide called mycolactone, making this molecule an attractive candidate target
for diagnosis and disease monitoring. Whether mycolactone diffuses from ulcerated lesions in clinically accessible samples
and is modulated by antibiotic therapy remained to be established.
Methodology/Principal Finding: Peripheral blood and ulcer exudates were sampled from patients at various stages of
antibiotic therapy in Ghana and Ivory Coast. Total lipids were extracted from serum, white cell pellets and ulcer exudates
with organic solvents. The presence of mycolactone in these extracts was then analyzed by a recently published, field-
friendly method using thin layer chromatography and fluorescence detection. This approach did not allow us to detect
mycolactone accurately, because of a high background due to co-extracted human lipids. We thus used a previously
established approach based on high performance liquid chromatography coupled to mass spectrometry. By this means, we
could identify structurally intact mycolactone in ulcer exudates and serum of patients, and evaluate the impact of antibiotic
treatment on the concentration of mycolactone.
Conclusions/Significance: Our study provides the proof of concept that assays based on mycolactone detection in serum
and ulcer exudates can form the basis of BU diagnostic tests. However, the identification of mycolactone required a
technology that is not compatible with field conditions and point-of-care assays for mycolactone detection remain to be
worked out. Notably, we found mycolactone in ulcer exudates harvested at the end of antibiotic therapy, suggesting that
the toxin is eliminated by BU patients at a slow rate. Our results also indicated that mycolactone titres in the serum may
reflect a positive response to antibiotics, a possibility that it will be interesting to examine further through longitudinal
studies.
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Introduction
Buruli ulcer (BU), caused by Mycobacterium ulcerans,i st h et h i r dm o s t
common mycobacterial disease after tuberculosis and leprosy and
represents an emerging threat [1,2]. Since the late 1980s, the disease
has been developing throughout West and Central Africa, prompting
the WHO in 1998 to initiate an awareness and control campaign
(http://www.who.int/gtb-buruli). Although efficient [3,4,5,6,7], cur-
rent treatment protocols recommend the daily administration of oral
rifampicin and intramuscular streptomycin for 8 weeks, with
additional surgical intervention when necessary. To control the
emergence of BU and to improve the management of the disease, it is
vital to develop new tools for early diagnosis and treatment
monitoring. A distinctive feature of M. ulcerans among human
pathogens is the production of mycolactone [8], a macrocyclic
polyketide playing a critical role in bacterial virulence (reviewed in
[9,10]). We have recently demonstrated the presence of intact
mycolactone in punch biopsies from all forms of BU disease, before
and during antibiotic therapy [11]. Moreover, there is evidence from
mouse studies that mycolactone may diffuse into the peripheral blood
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5[12]. Here we used chemical approaches to determine if mycolactone
is present in blood samples and ulcer exudates obtained non-
invasively at various stages of antibiotic therapy.
Methods
Patient cohorts
Patients were recruited if they met the WHO clinical case
definition of BU disease; were not pregnant; had no history of
tuberculosis, leprosy, or liver, kidney, or hearing impairment. All
subjects provided written informed consent (thumb print of parent
or guardian in the case of children, depending on literacy). A
cross-section of patients with BU disease were recruited which
included a spectrum of patients yet to initiate antibiotic therapy,
some at various stages of antibiotic treatment and few who had
completed treatment. Healthy controls from the same endemic
area were included. In Ghana, patients were recruited by local
health workers from villages near Tepa Government Hospital in
the Ahafo Ano North District of Ghana, where there is a high
prevalence of BU. The study protocol was approved by the ethics
review committees at the School of Medical Sciences, Kwame
Nkrumah University of Science and Technology, Kumasi, Ghana.
In Ivory Coast, patients were either recruited from the Djekanou
General Hospital or detected by a mobile medical team actively
screening the district of Abidjan. The study protocol was approved
by the national ethic review committee.
Diagnosis and treatment
To confirm the clinical diagnosis, punch biopsy specimens of 4-
mm diameter (Ghana) or ulcer exudates (Ivory Coast) were tested
by PCR for the IS2404 repeat sequence, which is characteristic of
M. ulcerans. Positive patients were treated with 10 mg/kg oral
rifampicin and 15 mg/kg intramuscular streptomycin daily,
administered at village health posts under direct observation,
according to the WHO recommendations. Only IS2404 positive
samples were considered for analysis of mycolactone presence.
Mycolactone standard
Mycolactone was extracted from M. ulcerans 1615 (ATCC
35840), as previously described [12]. In brief, bacteria were
cultivated in Middlebrook 7H9 broth (Difco) enriched with 10%
oleic acid-albumin-dextrose-catalase (OADC, Becton Dickinson)
for 4 weeks in spinner flasks at 30uC. Total lipids were extracted
from bacterial cell pellets with 2/1 CHCl3/MeOH (v/v) for 20 h
at 4uC. After separation from the aqueous phase following the
addition of 20% H2O (w/v), the organic phase was dried. The
resulting material was resuspended in ice-cold acetone and
Author Summary
Mycolactone is a diffusible cytotoxin produced by
Mycobacterium ulcerans, the causative agent of the skin
disease Buruli ulcer. In a previous study using animal
models, we reported that mycolactone released by
cutaneous foci of infection gains access to the peripheral
blood. Here we investigated whether mycolactone circu-
lates in human patients and is detectable in clinically
accessible samples. Using a combination of solvent
extraction, high performance liquid chromatography and
mass spectrometry analysis, we found that structurally
intact mycolactone was present in ulcer exudates obtained
from wound swabs and in the serum of patients.
Unexpectedly, high titres of mycolactone were detected
in ulcer exudates after completion of antibiotic treatment.
In contrast, mycolactone could only be detected in the
serum of newly diagnosed patients. Our results demon-
strate that mycolactone detection in serum and ulcer
exudates may be used to diagnose BU. Moreover, they
suggest that the kinetics of mycolactone concentration in
serum may be indicative of the clinical response of
patients to antibiotic therapy.
Figure 1. Comparison of the performances of the TLC-Fluo and HPLC approaches for mycolactone quantitative detection. A
representative picture of the fluorescent signals and elution peaks obtained for mycolactone (10–500 ng) detection by TLC-Fluo (A) and HPLC (B) are
shown, with the corresponding standard curves (C). Arbitrary units correspond to fluorescence intensity of the mycolactone band (TLC-Fluo) and area
of the mycolactone elution peak (HPLC). Similar results were obtained in at least three independent experiments.
doi:10.1371/journal.pntd.0001237.g001
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then dried, resuspended in ethanol, and loaded onto a silica gel
TLC plate and eluted with 90/9/1 CHCl3/MeOH/H2O as the
mobile phase. The yellow band corresponding to mycolactone
(retention factor of 0.2) was then scraped and mycolactone eluted
from silica particles using 2/1 CHCl3/MeOH (v/v). Following
solvent evaporation, purified mycolactone was resuspended in
ethanol. The concentration of the resulting solution was
determined by UV absorption, as described [13].
Mycolactone detection by coupling to 2-naphtalene
boronic acid (TLC-Fluo)
As recently described [13], mycolactone or lipid extracts were
applied to a silica gel TLC plate and eluted with 90/9/1 CHCl3/
MeOH/H2O as the mobile phase. The eluted TLC plate was
briefly warmed on a hot plate to evaporate the organic solvents,
and quickly immersed into a 0.1 M acetone solution of 2-
naphtalene boronic acid (Sigma), then heated to 100uC for 5,10
seconds. The TLC plate was then irradiated with a UV reader
equipped with a 312 nm lamp.
Mycolactone detection by HPLC/MS/MS
Mycolactone or lipid extracts were also analyzed by High
Performance Liquid Chromatography coupled to Mass Spectrom-
etry (HPLC/MS/MS). We used a Shimadzu HPLC fitted with a
BDS Hypersil C8 column (5 mm, 4.66250 mm), with UV
detection at 360 nm. Mycolactone was eluted by a 60 min
gradient from 50 to 95% acetonitrile in water after 22 min.
Fractions of interest were collected in glass tubes and analysed on a
QSTAR XL, AB-MDS-SCIEX mass spectrometer with an
electrospray ion source and the following parameters: ion spray
voltage (IS), 5200 v; curtain gas (CUR), 25; gas 1 (GS1), 5;
Figure 2. Structurally intact mycolactone is detected in ulcer exudates of BU patients. (A) Example of the fluorescence signals given by
ulcer exudates (lanes 2–5), compared to pure mycolactone (lane 1) following analysis by TLC-Fluo. The band corresponding to mycolactone is
designated by an asterisk. (B) HPLC elution profiles are shown for reference mycolactone (100 ng) and for one representative ulcer exudate among
the 20 positive ones. The corresponding MS/MS spectra are presented, with mycolactone parent ion (P.I.) and products designated by asterisks.
Similar MS/MS spectra were obtained from HPLC elution peaks collected from three positive patients.
doi:10.1371/journal.pntd.0001237.g002
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declustering potential 2 (DP2), 15 v. Mycolactone was identified
by the presence of [M+Na]+ m/z 765.5. MS-MS parameters were:
ion spray voltage (IS), 6000 v; curtain gas (CUR), 25; gas 1 (GS1),
20; declustering potential (DP), 60 v; focusing potential (FP),
230 v; declustering potential 2 (DP2), 10 v; collision energy (CE),
60; collision gaz (CAD), 5. Data were collected and processed
through the Analyst QS 1.1 software from AB-MDS-Sciex.
Exudates
Wound swabs obtained from the undermined edges of
ulcerative lesions were soaked into 1 ml ethanol immediately after
sampling and stored in polypropylene collecting tubes at -20uC,
protected from light, until analysis. Ethanol solutions of exudates
were concentrated to a volume of 500 ml then processed to TLC-
Fluo and HPLC/MS/MS analyses.
Serum samples
Lipids were extracted from serum samples (1 ml) by sequential
additionof 4/1 MeOH (v/v), 1/1CHCl3 (v/v), and 3/1 H2O (v/v),
each step being followed by thorough mixing. The upper aqueous
phase was discarded and the bottom organic phase transferred to a
glass tube containing 3 ml of MeOH. The resulting solution was
centrifuged to sediment insoluble particulate matter. The soluble
organic phase was then dried and the resulting product re-
suspended in ethanol for TLC-Fluo and HPLC/MS/MS analyses.
Mononuclear cell pellets
Mononuclear cells were isolated from 10 ml whole blood by
differential sedimentation on Ficoll-Hypaque (GE Healthcare). Cell
pellets were then dried and stored at 220uC until lipid analysis. Total
lipids were extracted from cell pellets by addition of 1 ml 2/1 CHCl3/
MeOH (v/v) for 48 h at 4uC. The organic phase was recovered by
Table 1. Characteristics of patients and controls.




Befored 6 23.3 0/6 50
Duringe 13 16.7 7/6 100
Afterf 4 20.7 0/4 100







d 8 13.1 5/3 50
During
e 6 19.8 3/3 17
After
f 4 29.2 2/2 25
Ctrl
g 1 32.0 1/0 0
Serum samples




Befored 5 ND ND 60
Duringe 8 23.5 1/3 12
Afterf 4 19.7 2/5 0







d 15 21.1 9/6 0
Duringe 20 24.9 9/11 0
Afterf 7 24.7 4/3 0
Ctrlg 4 14.2 1/3 0
Mononuclear cells




Befored 3 33.3 1/2 0
Duringe 4 26.0 2/2 0
Afterf 5 19.6 0/5 0
Ctrlg 4 30.0 2/2 0
aMean age (year).
bM, males; F, females.
cPercentage of samples with signal superior to background.
dNewly diagnosed.
eTreated for 2 to 8 weeks.
fCompleted the treatment.
gHealthy control from the same endemic zone.
NA: not applicable; ND: not determined.
doi:10.1371/journal.pntd.0001237.t001
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resuspended in ethanol for TLC-Fluo and HPLC/MS/MS analyses.
Results
Efficacy of mycolactone extraction from biological
samples
We first compared the TLC-Fluo and HPLC/MS/MS ap-
proaches for mycolactone detection in the 0–500 ng range, using
purified mycolactone as a reference. Both methods were highly
sensitive, yielding a detectable signal with only 10 ng mycolactone
(Fig. 1A,B).Howeverthe fluorescent signalofmycolactone modified
by coupling to 2-naphtalene boronic acid was not a linear function
of its concentration, whereas the areas of mycolactone elution peaks
in HPLC were proportional to mycolactone concentration in the
10–500 ng domain (Fig. 1C). To evaluate the efficacy of
mycolactone extraction from biological samples, serum samples
(1 ml) or mononuclear cell pellets (10
6 cells) were spiked with
purified mycolactone. We then proceeded to solvent extraction as
described in the Methods section, and estimated the proportion of
recovered mycolactone using the above-described standard curves.
The estimated yields of extraction with organic solvents were of
20% from cell pellets and 10% from serum samples (not shown).
Severalcombinations of solvents weretried that didnot improve the
recovery of mycolactone.
Detection of mycolactone in ulcer exudates
Exudate samples were split into two equivalent parts, which
were analyzed in parallel for the presence of mycolactone by
HPLC/MS/MS or TLC-Fluo. We could not conclude on the
presence of mycolactone by TLC-Fluo, because of the co-
migration of auto-fluorescent compounds (Fig. 2A). Using HPLC
determination, elution peaks corresponding to mycolactone were
observed in 3/6 newly diagnosed patients and all patients
undergoing or completing their course of antibiotic treatment
(13/13, 4/4 respectively) (Table 1). To confirm that they
effectively contained mycolactone, elution peaks were collected
in three patients, and analyzed by MS/MS. In all of them, the
characteristic spectrum of mycolactone parent ion (m/z 765) and
products was observed [14], demonstrating the presence and
structural integrity of mycolactone in ulcer exudates (Fig. 2B).
Notably, the presence of mycolactone in these samples persisted
during and after completion of antibiotic therapy (Fig. 3).
Detection of mycolactone in blood mononuclear cells
Since our previous experiments in experimentally infected mice
demonstrated the presence of mycolactone in circulating mononu-
clear cells, we analyzed this biological material in BU patients.
Whole blood (10 ml) was collected in patients from Ghana and
Ivory Coast at various stages of the disease (Table 1) and
mononuclear cells were isolated by Ficoll gradient centrifugation.
However, no mycolactone could be identified in any of the samples
tested (n=52) by TLC-Fluo or HPLC/MS/MS (not shown).
Detection of mycolactone in serum
Total lipids were extracted from 1 ml serum samples then
analyzed by TLC-Fluo (Ghana samples) or HPLC (Ivory Coast
samples) (Table 1). Again, the identification of mycolactone by
TLC-Fluo was difficult, because of the co-migration of auto-
fluorescent compounds (Fig. 4A). Using HPLC, mycolactone
detection was also hampered by the co-elution of UV-absorbing
contaminants (Fig. 4B). We could nevertheless identify mycolac-
tone-like peaks in 3/5 newly diagnosed patients, 1/8 patients
undergoing treatment, and 0/4 patients completing treatment.
These peaks were collected in two patients and analyzed by MS/
MS. In both of them, the characteristic spectrum of mycolactone
parent and product ions could be observed (Fig. 4B). The
concentration of circulating mycolactone was evaluated in positive
samples by measuring the area of mycolactone elution peaks and
subtracting the mean signal of two healthy controls (Fig. 5).
Calculated values were in the 40–200 ng/ml range.
Discussion
In the present study, we investigated whether mycolactone was
detectable in easily accessible samples of BU patients. We used two
chemical approaches, both requiring the extraction of total lipids
by organic solvents. The efficacy of this extraction step, as
measured by addition of pure mycolactone to control samples, was
mediocre and reduced dramatically the sensitivity of the following
Figure 3. Mycolactone presence is maintained in ulcer exudates during antibiotic therapy. Mean concentration of mycolactone in ulcer
exudates harvested before (0 week), during (2 to 8 weeks of treatment), or after completion of the 8 week antibiotic treatment. Dashed horizontal line
indicates detection threshold.
doi:10.1371/journal.pntd.0001237.g003
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limited yield of extraction may be that mycolactone associates with
biomolecules preventing solvent access, a possibility that we are
currently testing by studying the impact of various thermal and
enzymatic treatments. If the efficacy and selectivity of mycolactone
extraction can be improved, the recently described and field-
friendly TLC-Fluo detection method may still be an option for
mycolactone-based point-of-care diagnostic tests. If not, it will be
necessary to design alternative approaches that do not require this
purification step.
Using HPLC/MS/MS, we could demonstrate that mycolactone
gains access to the peripheral blood of human patients. In previous
studies in the mouse model, we detected structurally intact
mycolactone in mononuclear cell fractions of pooled blood
samples harvested from mice subcutaneously injected with
mycolactone, or experimentally infected with M. ulcerans [12]. In
the present work, mycolactone could not be identified in blood
mononuclear cells. This cell subpopulation was isolated from
10 ml whole blood, and we estimated the maximum yield of
mycolactone extraction from mononuclear cell pellets to 20%. If
mycolactone effectively reaches blood mononuclear cells in human
patients, its cellular concentration may be too low to be detected in
the accessible volume of blood. Alternatively, mycolactone may be
unstable in the conditions used in the present study to isolate and
store mononuclear cell pellets.
In contrast, we were able to demonstrate the presence of
structurally intact mycolactone in the serum of 3/5 newly
diagnosed BU patients (Table 1). This novel information provides
the essential proof of concept for the design of BU diagnostic tests
based on mycolactone detection in peripheral blood. Since
mycolactone is extracted from serum samples with low efficacy,
the number of positive samples and the calculated concentrations
of circulating mycolactone are probably underestimated in this
study. Whether mycolactone kinetics in serum could be employed
to monitor the response to antibiotic treatment will certainly be
interesting to investigate further. Our preliminary results suggest
Figure 4. Structurally intact mycolactone is detected in serum samples of BU patients. (A) Example of the fluorescence signals given by
serum samples (lanes 2–9), following lipid extraction and analysis by TLC-Fluo. Controls include 1 mg pure mycolactone (lane 1), lipids extracted from
a negative serum (lane 10), and then spiked with 1 mg mycolactone (lane 11). The band corresponding to mycolactone is designated by an asterisk.
(B) Representative HPLC elution profiles of lipids extracted from serum samples are shown for one healthy control out of 5, and one BU patient
among the 4 positive ones. The corresponding MS/MS spectra show the presence of the parent and product ions of mycolactone in this positive
sample. Similar results were obtained in a second one.
doi:10.1371/journal.pntd.0001237.g004
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mycolactone concentration (Fig. 5) showed a tendency to decrease
in the serum during antibiotic therapy. If confirmed by
longitudinal studies, the decay of circulating mycolactone during
antibiotic therapy would provide an explanation to the recovery of
cellular immune responses during treatment [15,16] and after
surgical excision of BU lesions [17].
Here we considered patients at ulcerative stages of the disease. BU
is usually diagnosed on the basis of clinical symptoms, as the
identification of M. ulcerans by means of cultures or PCR requires
dedicated facilities and specialized equipment (reviewed in [18]).
Common differential diagnoses of BU include other tropical ulcers
(venous, phagedenic, neurogenic), leishmaniasis, yaws and squamous
cell carcinoma. The presence of biologically active mycolactone was
recently demonstrated in skin biopsies of BU patients [11]. Here we
show that mycolactone can be detected in ulcer exudates obtained
non-invasively from wound swabs, in a structurally intact formand at
concentrations in the 50–200 ng/ml range, which strongly suggests
that mycolactone detection in exudates may be of interest for
differential diagnosis of the ulcerative forms. Whether mycolactone is
present at pre-ulcerative stages in fine-needle aspirates and in the
peripheral blood is currently under investigation.
Weobservedsignificantamountsofmycolactoneinexudatesatthe
e n do fa n t i b i o t i ct h e r a p y .I ns o m ei n s t a n c e s ,a n t i b i o t i cp r e s s u r em a y
not efficiently block, and could even enhance the production of a
toxin. For instance, in patients infected with E. coli O157:H7, the use
of antimicrobials has been discouraged because it stimulates toxin
production and augments the risk of detrimental, or even fatal
complications [19]. Whether antibiotics promote the expression of
mycolactone by M. ulcerans is unknown. However, their efficacy at
killing M. ulcerans is not questionable with 4 weeks of treatment
leading to culture negativity [3,4,5,6,7]. Although a stimulatory effect
of antibiotics on mycolactone production cannot be excluded, our
observation suggests that mycolactone persists in cutaneous tissues
after the demise of M. ulcerans. Since mycolactone displays inherent
ulcerative properties [8], this phenomenon may explain why some
BU take considerable time to heal despite remaining culture negative.
The administration of antibiotics is sometimes associated with
adverse reactions, excessive inflammation and pain sensation, that
paradoxically make the symptoms of infection worse [20]. It is possible
that in BU, like in the Jarish-Heixheimer reaction in syphilis or in
relapsing fevers, efficient killing of M. ulcerans by antibiotics leads to the
sudden and massive release of bacterial antigens locally that act as
immuno-stimulants. Mycolactone displays potent immunosuppressive
properties in vitro that are thought to contribute to the cellular response
defects of BU patients [21,22,23,24,25]. The rapid decline of
mycolactone from the systemic circulation during treatment may thus
provoke exuberant inflammatory responses at the level of the lesions,
and cause the paradoxical reactions observed in BU disease [26].
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